CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration
between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical
stage company bringing the transformative potential of synthetic
biology to medicine, has been recognized by the Air Force Research
Laboratory (AFRL) as a Biotechnology Grand Challenge Winner. One of
four winning teams, the joint team comprised of MIT and Synlogic was awarded $1 million in an effort to spearhead innovation
among small businesses in the field of biotechnology for the
Department of Defense.
"We are honored to be recognized by the AFRL and are thrilled to
collaborate with Synlogic to achieve this success," said
Christopher Voigt, MIT Professor of
Biological Engineering and Principal Investigator for the MIT Voigt
Lab. "Our challenge was determining which organization would
possess the proven expertise in both the development and
manufacturing of novel biotherapeutic products, and we couldn't be
happier that we have found that partner in Synlogic."
Christopher Voigt is an expert in
synthetic biology and biotechnology with extensive research
programs in defense, chemistry/materials, and agriculture. The
focus of the Voigt Lab is to develop new experimental and
theoretical methods to push the scale of genetic engineering, with
the ultimate objective of genome design. This will impact the
engineering of biology for a broad range of applications, including
agriculture, materials, chemicals, and medicine. Professor Voigt's
research spans applications for the Army, Navy, and Air Force, and
he works closely with scientists across the service labs as well as
hosting DoD researchers at MIT.
"Our internal and fully integrated Process Development &
Manufacturing Sciences organization has demonstrated leading
technical expertise in the field of Synthetic Biotic medicines and
we look forward to applying innovative solutions for today's
real-life challenges," said Antoine
Awad, Synlogic's Chief Operating Officer. "As we
develop our internal pipeline we are excited to leverage our core
capabilities to advance innovative partner projects, such as
applying our bioprocess and manufacturing to advance the goals of
the AFRL."
Together, Synlogic and the Voigt Lab will collaborate to
generate and manufacture engineered strains by performing an
assessment of process manufacturability, with optimization
performed to maximize high cell density growth and high end of
fermentation (EOF) viability. The goal of this work is to produce a
live bacterial therapeutic that would improve pilot performance and
decision-making when battling fatigue during long
missions.
Learn more about Synlogic at www.synlogictx.com.
About Synlogic
Synlogic™ is bringing the transformative potential of synthetic
biology to medicine. With a premiere synthetic biology platform
that leverages a reproducible, modular approach to microbial
engineering, Synlogic designs Synthetic Biotic medicines that
target validated underlying biology to treat disease in new ways.
Synlogic's proprietary pipeline includes Synthetic Biotic medicines
for the treatment of metabolic disorders including Phenylketonuria
(PKU) and Enteric Hyperoxaluria (HOX). The company is also building
a portfolio of partner-able assets in immunology and oncology.
Forward-Looking Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, clinical development plans, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. In addition, when or
if used in this press release, the words "may," "could," "should,"
"anticipate," "believe," "estimate," "expect," "intend," "plan,"
"predict" and similar expressions and their variants, as they
relate to Synlogic may identify forward-looking statements.
Examples of forward-looking statements, include, but are not
limited to, statements regarding the potential of Synlogic's
platform to develop therapeutics to address a wide range of
diseases including: cancer, inborn errors of metabolism, and
inflammatory and immune disorders; the future clinical development
of Synthetic Biotic medicines; the approach Synlogic is taking to
discover and develop novel therapeutics using synthetic biology;
and the expected timing of Synlogic's clinical trials including the
Phase 1 study for SYNB1891 and SYNB8802 and the Phase 2 study of
SYNB1618, and availability of clinical trial data from that study
and other studies.
Actual results could differ materially from those contained in
any forward-looking statement as a result of various factors,
including: the uncertainties inherent in the clinical and
preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original
content:http://www.prnewswire.com/news-releases/joint-team-from-mit-and-synlogic-named-a-biotechnology-grand-challenge-winner-by-air-force-research-laboratory-301219762.html
SOURCE Synlogic, Inc.